Immunic is expected to report zero revenue and a consensus EPS loss of $0.93, with its current share price of $7.88 trading significantly below the average analyst target of $43.09.
Investors are primarily focused on update regarding the pivotal Phase 3 ENSURE-1 and ENSURE-2 data readouts for vidofludimus calcium in relapsing multiple sclerosis, which are anticipated in December 2026.
The company recently hosted a Progressive MS R&D Day in early November, highlighting exploratory data from the Phase 2 CALLIPER trial that supports the neuroprotective profile of its lead asset. Management has also emphasized a stable cash runway extending into late 2027, alleviating immediate funding concerns ahead of major clinical catalysts.